Do analysts recommend AGFY or LFCR?

Lifecore Biomedical has a consensus target price of $6.50, indicating a potential upside of 37.71%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, analysts plainly believe Lifecore Biomedical is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lifecore Biomedical 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend AGFY or LENZ?

LENZ Therapeutics has a consensus price target of $28.80, indicating a potential upside of 508.88%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LENZ Therapeutics 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38

Is AGFY or LENZ more profitable?

Agrify has a net margin of -424.11% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat Agrify's return on equity. Company Net Margins Return on Equity Return on Assets Agrify -424.11% -185.90% -72.67% LENZ Therapeutics -586.74% -53.39% -49.14%

Do analysts rate MENS or AGFY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, MENS or AGFY?

Jyong Biotech has higher earnings, but lower revenue than Agrify. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Agrify $12.26M 3.63 -$41.75M -$22.65 N/A

Is MENS or AGFY more profitable?

Jyong Biotech has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Jyong Biotech's return on equity of 0.00% beat Agrify's return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Agrify -424.11% -185.90% -72.67%

Do analysts prefer CRDL or AGFY?

Cardiol Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 372.22%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Agrify (AGFY) Competitors

$22.22 +1.63 (+7.93%)

As of 08/13/2026

Compare

AGFY vs. LFCR, LENZ, AARD, MENS, and CRDL

Should you buy Agrify stock or one of its competitors? Agrify's main competitors and comparable companies include Lifecore Biomedical (LFCR), LENZ Therapeutics (LENZ), Aardvark Therapeutics (AARD), Jyong Biotech (MENS), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Agrify compare to Lifecore Biomedical?

Agrify (NASDAQ:AGFY) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Lifecore Biomedical had 1 more articles in the media than Agrify. MarketBeat recorded 1 mentions for Lifecore Biomedical and 0 mentions for Agrify. Lifecore Biomedical's average media sentiment score of 1.89 beat Agrify's score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Agrify	Neutral
Lifecore Biomedical	Very Positive

Lifecore Biomedical has higher revenue and earnings than Agrify. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.63	-$41.75M	-$22.65	N/A
Lifecore Biomedical	$128.87M	1.39	-$40.50M	-$1.07	N/A

Lifecore Biomedical has a consensus target price of $6.50, indicating a potential upside of 37.71%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, analysts plainly believe Lifecore Biomedical is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.0% of Agrify shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 2.2% of Agrify shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Agrify has a beta of 9.96, meaning that its share price is 896% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Lifecore Biomedical has a net margin of -29.93% compared to Agrify's net margin of -424.11%. Lifecore Biomedical's return on equity of 0.00% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Summary

Lifecore Biomedical beats Agrify on 13 of the 16 factors compared between the two stocks.

How does Agrify compare to LENZ Therapeutics?

Agrify (NASDAQ:AGFY) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

6.0% of Agrify shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 2.2% of Agrify shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LENZ Therapeutics has a consensus price target of $28.80, indicating a potential upside of 508.88%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Agrify has a net margin of -424.11% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Agrify has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.63	-$41.75M	-$22.65	N/A
LENZ Therapeutics	$19.09M	7.79	-$82.13M	-$4.09	N/A

Agrify has a beta of 9.96, meaning that its share price is 896% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

In the previous week, LENZ Therapeutics had 19 more articles in the media than Agrify. MarketBeat recorded 19 mentions for LENZ Therapeutics and 0 mentions for Agrify. LENZ Therapeutics' average media sentiment score of 0.35 beat Agrify's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Agrify	Neutral
LENZ Therapeutics	Neutral

Summary

LENZ Therapeutics beats Agrify on 12 of the 16 factors compared between the two stocks.

How does Agrify compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Aardvark Therapeutics had 6 more articles in the media than Agrify. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 0 mentions for Agrify. Aardvark Therapeutics' average media sentiment score of 1.26 beat Agrify's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aardvark Therapeutics	Positive
Agrify	Neutral

Aardvark Therapeutics has a beta of 3.81, meaning that its stock price is 281% more volatile than the broader market. Comparatively, Agrify has a beta of 9.96, meaning that its stock price is 896% more volatile than the broader market.

Aardvark Therapeutics currently has a consensus price target of $16.30, indicating a potential upside of 149.24%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aardvark Therapeutics is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

6.0% of Agrify shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Agrify shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Agrify has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Agrify	$12.26M	3.63	-$41.75M	-$22.65	N/A

Aardvark Therapeutics has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Aardvark Therapeutics' return on equity of -71.54% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Agrify	-424.11%	-185.90%	-72.67%

Summary

Aardvark Therapeutics beats Agrify on 11 of the 16 factors compared between the two stocks.

How does Agrify compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Jyong Biotech has higher earnings, but lower revenue than Agrify.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Agrify	$12.26M	3.63	-$41.75M	-$22.65	N/A

Jyong Biotech has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Jyong Biotech's return on equity of 0.00% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Agrify	-424.11%	-185.90%	-72.67%

6.0% of Agrify shares are held by institutional investors. 2.2% of Agrify shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Jyong Biotech has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market. Comparatively, Agrify has a beta of 9.96, suggesting that its share price is 896% more volatile than the broader market.

In the previous week, Jyong Biotech had 1 more articles in the media than Agrify. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for Agrify. Jyong Biotech's average media sentiment score of 1.89 beat Agrify's score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Very Positive
Agrify	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Jyong Biotech beats Agrify on 7 of the 11 factors compared between the two stocks.

How does Agrify compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Cardiol Therapeutics has higher earnings, but lower revenue than Agrify. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Agrify	$12.26M	3.63	-$41.75M	-$22.65	N/A

Cardiol Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Agrify has a beta of 9.96, meaning that its stock price is 896% more volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Cardiol Therapeutics' return on equity of -180.44% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Agrify	-424.11%	-185.90%	-72.67%

In the previous week, Cardiol Therapeutics had 4 more articles in the media than Agrify. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 0 mentions for Agrify. Cardiol Therapeutics' average media sentiment score of 1.40 beat Agrify's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Positive
Agrify	Neutral

Cardiol Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 372.22%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 6.0% of Agrify shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 2.2% of Agrify shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cardiol Therapeutics beats Agrify on 11 of the 15 factors compared between the two stocks.

Get Agrify News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGFY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGFY vs. The Competition

Export

Metric	Agrify	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44.51M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-0.98	775.15	269.06	25.28
Price / Sales	3.63	743.50	592.57	87.62
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	2.12	11.60	12.91	6.24
Net Income	-$41.75M	$2.77B	$3.45B	$347.60M
7 Day Performance	0.65%	0.17%	1.12%	1.07%
1 Month Performance	-1.14%	0.35%	1.79%	1.03%
1 Year Performance	-28.29%	161.52%	67.69%	20.77%

Agrify Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGFY Agrify	N/A	$22.22 +7.9%	N/A	-33.6%	$44.51M	$12.26M	N/A	140
LFCR Lifecore Biomedical	1.9591 of 5 stars	$4.35 -0.9%	$6.50 +49.4%	-38.9%	$164.67M	$128.87M	N/A	690	Positive News
LENZ LENZ Therapeutics	3.0861 of 5 stars	$5.05 +1.2%	$29.80 +490.1%	-88.3%	$156.62M	$19.09M	N/A	110	Trending News Earnings Report Analyst Downgrade Analyst Revision
AARD Aardvark Therapeutics	2.9759 of 5 stars	$7.27 +2.7%	$16.30 +124.2%	-42.8%	$154.94M	N/A	N/A	18	Positive News Earnings Report
MENS Jyong Biotech	N/A	$2.04 +2.0%	N/A	-94.4%	$152.05M	N/A	N/A	31	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGFY) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agrify (AGFY) Competitors

AGFY vs. LFCR, LENZ, AARD, MENS, and CRDL

How does Agrify compare to Lifecore Biomedical?

Summary

How does Agrify compare to LENZ Therapeutics?

Summary

How does Agrify compare to Aardvark Therapeutics?

Summary

How does Agrify compare to Jyong Biotech?

Summary

How does Agrify compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGFY vs. The Competition

Agrify Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agrify (AGFY) Competitors

AGFY vs. LFCR, LENZ, AARD, MENS, and CRDL

How does Agrify compare to Lifecore Biomedical?

Does the media prefer AGFY or LFCR?

Which has higher valuation and earnings, AGFY or LFCR?

Do analysts recommend AGFY or LFCR?

Do insiders and institutionals hold more shares of AGFY or LFCR?

Which has more volatility and risk, AGFY or LFCR?

Is AGFY or LFCR more profitable?

Summary

How does Agrify compare to LENZ Therapeutics?

Do insiders & institutionals believe in AGFY or LENZ?

Do analysts recommend AGFY or LENZ?

Is AGFY or LENZ more profitable?

Which has preferable earnings & valuation, AGFY or LENZ?

Which has more risk & volatility, AGFY or LENZ?

Does the media prefer AGFY or LENZ?

Summary

How does Agrify compare to Aardvark Therapeutics?

Does the media prefer AARD or AGFY?

Which has more volatility & risk, AARD or AGFY?

Do analysts recommend AARD or AGFY?

Do institutionals and insiders believe in AARD or AGFY?

Which has stronger valuation & earnings, AARD or AGFY?

Is AARD or AGFY more profitable?

Summary

How does Agrify compare to Jyong Biotech?

Which has stronger valuation and earnings, MENS or AGFY?

Is MENS or AGFY more profitable?

Do insiders & institutionals hold more shares of MENS or AGFY?

Which has more volatility & risk, MENS or AGFY?

Does the media prefer MENS or AGFY?

Do analysts rate MENS or AGFY?

Summary

How does Agrify compare to Cardiol Therapeutics?

Which has stronger earnings and valuation, CRDL or AGFY?

Which has more risk & volatility, CRDL or AGFY?

Is CRDL or AGFY more profitable?

Does the media prefer CRDL or AGFY?

Do analysts prefer CRDL or AGFY?

Do insiders and institutionals hold more shares of CRDL or AGFY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGFY vs. The Competition

Agrify Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools